Ashutosh Tewari, MD
- PROFESSOR AND SYSTEM CHAIR | Urology
- PROFESSOR | Oncological Sciences
Ashutosh (Ash) K. Tewari, MD, Chairman, Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai is a world-renowned urologist and prostate cancer specialist. As Director of the Department of Urology, he leads a multidisciplinary team committed to improving prostate cancer treatment, research, and education. To date, he has performed over 5,000 robotic radical prostatectomy surgeries. The Tewari Lab is working on unlocking the genomic causes of prostate cancer and translating genomic information to practical physician application through imaging. In 2012, he was awarded the American Urological Association’s Gold Cystoscope Award. This honor is given annually to the urologist who has contributed significantly to the field within 10 years of completing residency. Dr. Tewari holds several leadership positions domestically and internationally.
Dr. Tewari received his undergraduate and medical degrees at GSVM Medical College (Kanpur, India). During medical school he was awarded 17 Gold Medals for outstanding performance on university exams. Dr. Tewari completed his first urology residency at Sanjay Gandhi Post Graduate Institute of Medical Sciences (Lucknow, India). He completed fellowships in urologic-oncology at University of California, San Francisco and the University of Florida (Gainesville, FL). In 2004, he completed his second urology residency at Henry Ford Hospital (Detroit, Michigan). While at Henry Ford, Dr. Tewari was part of the team that performed the first robotic radical prostatectomy in the United States.
Dr. Tewari’s case series is one of the largest in the world and his outcomes are considered the gold standard for this procedure. Dr. Tewari’s clinical expertise in prostate cancer includes targeted biopsies, cystoscopies, robotic prostatectomies, as well as the management of active surveillance prostate cancer patients. He has also initiated clinical protocols investigating the utility of focal therapy platforms for the treatment of prostate cancer. Dr. Tewari has been consecutively listed in New York Magazine’s Top Doctors issue since 2006. Learn more at his Center for Prostate Cancer at http://www.prostatecancercenternyc.com.
Dr. Tewari’s research approaches the problem of prostate cancer from distinct perspectives.
His outcomes research group is investigating the epidemiological effects of prostate cancer. He is also investigating several novel imaging techniques for identifying prostate cancer imaging biomarkers. Dr. Tewari is also working to unlock the genomic causes of prostate cancer.
As a researcher, Dr. Tewari has authored over 250 peer-reviewed articles, book chapters, and textbooks on prostate cancer and robotic surgery. This includes several high-impact articles in Nature, Cell, and PNAS. Most recently he has edited Prostate Cancer: A Comprehensive Perspective (Elsevier 2013).
In addition to his publications, Dr. Tewari is the recipient of three major NIH Federal Research Awards. This includes an R01 grant, in which he serves as Principal Investigator, investigating the utility of multiphoton microscopy during prostate cancer treatment. Dr. Tewari also serves as site-PI for the NIH/NCI The Cancer Genome Atlas Tissue Source Site and the NIH/NCI Early Detection Research Network. In addition to his federal funding, Dr. Tewari is currently funded by the Prostate Cancer Foundation, Boston Scientific, and Medtronic. He has initiated collaborative work with several other leading institutions including Cold Spring Harbor Laboratory, the Broad Institute of MIT and Harvard, The Koch Institute for Integrative Cancer Research at MIT, Dana-Farber Cancer Institute, and Rockefeller University,
Dr. Tewari has trained over 30 fellows and residents in robotics. His fellows have gone on to establish successful prostate cancer programs in Canada, Great Britain, India, Japan, and Singapore. Dr. Tewari hosts an annual international prostate cancer symposium. Each year nearly 1000 attendees attend this symposium to discuss the latest breakthroughs and emerging topics in prostate cancer treatment and research. The proceedings of this meeting are covered by European Urology (the urology journal with the highest impact factor).
Dr. Tewari is affiliated with over 40 professional associations and organizations, including:
-Member, American Urological Association
-Member, Society of Minimally Invasive Surgery
-Member, Society of Robotic Surgery (SRS)
-Member, Society of Urologic Oncology (SUO)
-Fellow, New York Academy of Medicine
-Associate Editor, AUA News
-Associate Editor, BJUI
-Reviewer, Journal of Urology
-Reviewer, European Urology
American Board of Urology
- Prostate Cancer Screening
- Prostate-Specific Antigen (PSA) Test
- Robotic Prostate Surgery
Multi-Disciplinary Training AreasCancer Biology [CAB], Pharmacology and Therapeutics Discovery [PTD]
MBBS, G.S.V.M. Medical College
Residency, Urology, Henry Ford Hospital
Fellowship, Transplant, University of Liverpool
Fellowship, Urology Oncology, University of Florida
Fellowship, Urology Oncology, Henry Ford Hospital
Gold Cytoscope Award
Most Compassionate Doctor Award
First Prize Best Abstract
Yahya Cohen Memorial Lecture and Medal
American Society of Clinical Oncology Merit Award
BJU International Visiting Professor Award
America's Best Doctors